Amedica Corp. closed its underwritten public offering of units, priced at $1,000 apiece, with gross proceeds of $15 million.
Each unit comprised of one series B convertible preferred share and warrants to buy up to 758 common shares.
The warrants are initially exercisable at $1.60 per share and expire five years from the issue date.
Maxim Group LLC served as the sole book-running manager for the offering.
Salt Lake City, Utah-based Amedica is a commercial-stage biomaterial company, which develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the U.S. Europe, and South America.
